German medical biotech makes world class showing at Bio International
Germany’s medical biotechnology industry presented its major league capabilities at Bio International in Philadelphia. More than 50 German companies, regional biotech organizations, and clusters of excellence were at the German pavilion from June 3 to June 6 for the world’s top convention for the global biotechnology industry.
This year’s Bio International – with the slogan “It Starts with One” – was dedicated to setting the course for the biotechnology industry in the coming years. More than 17,000 people from 65 countries took part in the mammoth event, which featured more than 1,800 exhibitors and 400 expert presentations.
A record number 48,500 partnering meetings were held to break the Guinness world record set by Bio International in 2018. This year companies, academic institutions, patient groups, researchers, and experts from the regulatory and investment areas of the industry refined a range of strategies for going into the future. The new approaches are dedicated to continuing to optimize research and development (R&D), patient access, drug development, gene therapy, and diversity and inclusion.
At the German pavilion, the Export Initiative for the German Healthcare Industry, HEALTH MADE IN GERMANY, joined companies like Coriolis Pharma Research GmbH, pharma trace klinische Entwicklung GmbH, and regional government and research organizations such as BioM and the Fraunhofer Institute for Cell Therapy and Immunology. The initiative was there, among other things, to provide guidance and information for individuals and companies from abroad interested Germany’s healthcare products and services. One of Germany’s leading biotech industry organizations, BIO Deutschland, was at the conference to present the latest information and insights from the sector as well.
German medical biotech has long years of expertise in international R&D, including innovative contract research and partnerships. Just one of the companies at Bio International that reflects Germany’s experience was the BioPharma Translationsinstitut Dessau Forschungs GmbH (BTI). The institute specializes in “the translation of academic research into commercial use.” It held a presentation on an enzymatic tool it has developed for site-specific generation of antibody drug conjugates (ADCs).
Germany excels as well in the training of researchers and doctors from abroad who later establish companies in their own countries. For example, the CEO of the Chilean biotech company, Cells for Cells, Dr. Roberto Bobadilla, was at Bio International. He received his PhD from what is now known as the Helmholtz-Zentrum für Infektionsforschung (HZI), which specializes in the biochemistry of infection. He then went on to set up one of Latin America’s largest medical biotech enterprises.
At BIO International, HEALTH MADE IN GERMANY reported high demand for its publications, the Guide to Contract Research in Germany and the Medical Biotechnology Industry Profile. The initiative also has an online company directory for the country’s health industry, including medical biotechnology.
- The German Pavilion at Bio International: hosting more than 50 German biotech companies and organizations © Exportinitiative Gesundheitswirtschaft
- Exclusive Q&A session for German exhibitors on US-Biotech market© Exportinitiative Gesundheitswirtschaft
- Axel Lohse represents HEALTH MADE IN GERMANY in Philadelphia© Exportinitiative Gesundheitswirtschaft